TLDR: Velocity Clinical Research has partnered with Palantir Technologies to automate and streamline the complex payment reconciliation processes in clinical trials. This collaboration leverages Palantir’s agentic AI technology to transform a traditionally manual and error-prone task into an efficient, insight-driven operation, marking a significant advancement in modernizing clinical trial administration.
Velocity Clinical Research, a leading fully integrated site organization, has announced a strategic partnership with Palantir Technologies, a prominent data analytics and AI company, to revolutionize the payment reconciliation process within clinical trials. This collaboration aims to automate and streamline what has historically been a fragmented, time-consuming, and error-prone administrative challenge across the industry.
Clinical trial sites often grapple with various siloed systems for managing invoices, while sponsors and contract research organizations (CROs) maintain their own distinct financial systems. This disparity leads to significant inefficiencies and inconsistencies in reconciling payments, which are frequently tied to patient visits or performance-based milestones, making forecasting and budgeting particularly challenging.
The newly developed automated reconciliation solution integrates Palantir’s cutting-edge agentic AI technology with Velocity’s proprietary workflows. This innovative application has already demonstrated success in processing and reconciling customer payment report entries, yielding substantial time savings for Velocity’s Finance Collections team. By automating these routine tasks, the team is freed to concentrate on more strategic, high-value activities.
Raghu Punnamraju, Chief Technology Officer at Velocity, emphasized the transformative impact of this partnership, stating, “Velocity’s partnership with Palantir is one more example of how our size and scale is bringing new types of partnerships and innovation to the clinical trials sector. Automating the AR reconciliation process is a game-changer for clinical trial sites. Our collaboration turns months of manual effort into near-instantaneous insights, enabling our finance teams to focus on strategic, high-value work instead of wrestling with spreadsheets.”
This initiative builds upon Velocity’s prior technological advancements, which began last year with the successful piloting of generative AI agents. These agents were instrumental in identifying missed revenue opportunities, such as unrecorded monitoring visits, laying the groundwork for the broader automation project with Palantir. The current collaboration combines Velocity’s deep clinical operations expertise with Palantir’s industry-leading AI systems and modeling capabilities.
Also Read:
- EVERSANA Introduces AI-Powered ORCHESTRATE PV to Revolutionize Pharmacovigilance
- Major Pharmaceutical Companies Mark AI Adoption as Immediate Priority, Driving Increased Investment
The partnership signifies a major step towards modernizing clinical trial operations, promising enhanced efficiencies that will ultimately benefit sites, sponsors, and patients alike. Looking ahead, Velocity plans to extend this intelligent automation beyond financial workflows to other operational fields, with the ultimate goal of creating a continuously learning financial system that refines processes while ensuring human experts remain engaged in strategic decision-making.
